Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 83
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global FM market. The report identifies the key trends shaping and driving the global FM market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global FM sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.4 billion by 2018. The restricted growth in the market is due to the unavailability of approved drugs in the EU and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of newer therapies in late stage FM therapeutics pipeline. Currently, FDA (Food and Drug Administration) has approved three drugs for the treatment of FM. Lyrica (pregabalin) was the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and Savella (milnacipran) in January 2009. Marketing authorization of these drugs has been rejected by EMEA (European Medical Agency) due low effectiveness and high adverse reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in 2008, followed by Lyrica in 2009 and Savella in 2010. However, increasing prevalence and diagnosis is expected to drive the future FM therapeutic market.

Scope

The report provides information on the key drivers and challenges of the FM market. Its scope includes - 

- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to 2018. 

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as therapies based on SSRI and GABA agonist calcium channel blocker, sodium channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.

- Analysis of the current and future competition in the global FM market. Key market players covered are the Pfizer, Jazz Pharmaceuticals and UCB.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the FM therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 

- Develop business strategies by understanding the trends shaping and driving the global FM market. 

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global FM market in future. 

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 

- What’s the next big thing in the global FM market landscape? – Identify, understand and capitalize.